Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 174.45 2.56
Cipla Lt 557.40 8.38
Ong Corp 444.60 2.17
Tata Stl 519.20 1.10
Ntpc Ltd 140.10 1.74
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Cipla Limited
Cipla Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
BSE:500087NSE:CIPLABloomberg:CIPLA@INReuters:CIPL.BO
Market Lot: 1Face Value: 2ISIN Demat: INE059A01026
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
02-SEP-14 Cipla, leading drug maker, announced the launch of Serroflo, its Salmeterol/Fluticasone MDI, in Germany and Sweden. With this launch, Cipla opens the door for new, highly efficient treatments in the European healthcare market. Serroflo will substantially improve the affordability of fixed combinations in Europe and help manage health costs for respiratory treatment. 02-SEP-14 Cipla, leading drug maker, announces the launch of Serrofl...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Cipla jumps on launch of Serroflo in Germany and Sweden  -IRIS 02-Sep-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Mar-2014 (12)31-Mar-2013 (12)31-Mar-2012(12)
Net sales 90349.5080153.7068076.80
Other Income2802.802291.301182.70
Total Income93152.3082445.0069259.50
Cost of goods sold73907.6060832.8053956.30
OPBDIT19244.7021612.2015303.20
PAT13883.4015071.1011239.60
Gross Block---
Equity capital1605.801605.801605.80
EPS (Rs.)17.2918.77-
DPS (Rs.)---
BV (Rs.)---
P/E range (x)21.06 - 26.0316.02 - 23.18-
Debt / Equity (x)---
Operating margin (% of OI)20.726.222.1
Net margin (% of OI)14.918.316.2
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Mumbai Central
Mumbai
Maharashtra-400 008
PHONE
(022) 2309 5521 / 2302 5272
FAX
(022) 2300 8101
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer